Targeting Stem Cells with Hyperthermia: Translational Relevance in Cancer Patients

Oncology ◽  
2020 ◽  
Vol 98 (11) ◽  
pp. 755-762 ◽  
Author(s):  
Michele Ammendola ◽  
Giuseppe Currò ◽  
Riccardo Memeo ◽  
Lucia Stella Curto ◽  
Maria Luposella ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Cancer Survival ◽  
Therapeutic Approaches ◽  
Cancer Treatments ◽  
Biological Features ◽  
Expert Opinions ◽  
New Therapeutic Approaches ◽  
Radiotherapy Resistance ◽  
Small Subpopulation

<b><i>Background:</i></b> Tumor recurrences or metastases remain a major hurdle in improving overall cancer survival. In anticancer therapy, some patients inevitably develop chemo-/radiotherapy resistance at some point. Cancer stem cells are the driving force of tumorigenesis, recurrences, and metastases, contributing also to the failure of some cancer treatments. <b><i>Summary:</i></b> Emergent evidence suggests that stem cell diseases are at the base of human cancers, and tumor progression and chemo-/radiotherapy resistance may be dependent on just a small subpopulation of cancer stem cells. Hyperthermia can be a strong cancer treatment, especially when combined with radio- or chemotherapy. It is a relatively safe therapy, may kill or weaken tumor cells, and significantly increases the effectiveness of other treatments. However, these mechanisms remain largely unknown. A literature search was performed using PubMed including cited English publications. The search was last conducted in December 2019. Search phrases included “stem cells,” “hyperthermia,” “cancer,” and “therapy.” Abstracts, letters, editorials, and expert opinions were not considered for the drafting of the study. <b><i>Key Message:</i></b> Our goal was to focus on and to summarize different biological features of cancer stem cells and new therapeutic approaches using hyperthermia and its potential translation to human clinical trials.

New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia

2013 ◽  
Vol 57 (1-3) ◽  
pp. 34-43 ◽  
Author(s):  
Wendy Weston ◽  
Vineet Gupta ◽  
Rebecca Adkins ◽  
Roland Jurecic
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Aplastic Anemia ◽  
Therapeutic Approaches ◽  
Hematopoietic Stem ◽  
New Therapeutic Approaches

scholarly journals Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells

Oncotarget ◽  
2016 ◽  
Vol 7 (32) ◽  
pp. 51349-51364 ◽  
Author(s):  
Xin Zhao ◽  
Xiaoliang Liu ◽  
Guanjun Wang ◽  
Xue Wen ◽  
Xiaoying Zhang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Growth Factor ◽  
Cancer Stem Cells ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Radiotherapy Resistance

scholarly journals Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Alex Lyakhovich ◽  
Matilde E. Lleonart
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Cancer Survival ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
Cell Resistance ◽  
Normal Cells ◽  
Alternative Pathways ◽  
Detoxification Mechanisms ◽  
Insight Into

Cancer stem cells (CSCs) are highly resistant to conventional chemo- and radiotherapeutic regimes. Therefore, the multiple drug resistance (MDR) of cancer is most likely due to the resistance of CSCs. Such resistance can be attributed to some bypassing pathways including detoxification mechanisms of reactive oxygen and nitrogen species (RO/NS) formation or enhanced autophagy. Unlike in normal cells, where RO/NS concentration is maintained at certain threshold required for signal transduction or immune response mechanisms, CSCs may develop alternative pathways to diminish RO/NS levels leading to cancer survival. In this minireview, we will focus on elaborated mechanisms developed by CSCs to attenuate high RO/NS levels. Gaining a better insight into the mechanisms of stem cell resistance to chemo- or radiotherapy may lead to new therapeutic targets thus serving for better anticancer strategies.

scholarly journals Therapeutic Approaches to Target Cancer Stem Cells

Cancers ◽  
2011 ◽  
Vol 3 (3) ◽  
pp. 3331-3352 ◽  
Author(s):  
Arlhee Diaz ◽  
Kalet Leon
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Therapeutic Approaches ◽  
Target Cancer

scholarly journals Co-Expression of CD34, CD90, OV-6 and Cell-Surface Vimentin Defines Cancer Stem Cells of Hepatoblastoma, Which Are Affected by Hsp90 Inhibitor 17-AAG

Cells ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 2598
Author(s):  
Mieun Lee-Theilen ◽  
Julia R. Hadhoud ◽  
Giulietta Volante ◽  
Delaine D. Fadini ◽  
Julia Eichhorn ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Cell Surface ◽  
Hsp90 Inhibitor ◽  
Chemotherapeutic Drug ◽  
Therapeutic Approaches ◽  
Pediatric Solid Tumors ◽  
Tumor Research ◽  
And Migration ◽  
Emt Markers

Cancer stem cells (CSCs) are nowadays one of the major focuses in tumor research since this subpopulation was revealed to be a great obstacle for successful treatment. The identification of CSCs in pediatric solid tumors harbors major challenges because of the immature character of these tumors. Here, we present CD34, CD90, OV-6 and cell-surface vimentin (csVimentin) as reliable markers to identify CSCs in hepatoblastoma cell lines. We were able to identify CSC characteristics for the subset of CD34+CD90+OV-6+csVimentin+-co-expressing cells, such as pluripotency, self-renewal, increased expression of EMT markers and migration. Treatment with Cisplatin as the standard chemotherapeutic drug in hepatoblastoma therapy further revealed the chemo-resistance of this subset, which is a main characteristic of CSCs. When we treated the cells with the Hsp90 inhibitor 17-AAG, we observed a significant reduction in the CSC subset. With our study, we identified CSCs of hepatoblastoma using CD34, CD90, OV-6 and csVimentin. This set of markers could be helpful to estimate the success of novel therapeutic approaches, as resistant CSCs are responsible for tumor relapses.

Sign in / Sign up

Export Citation Format

Share Document